Call for Boxed Warning for Secondary Malignancies on CAR T-Cell Therapies Raises Alarm, But Key Questions Remain
Experts discuss the FDA’s call for a boxed warning for secondary T-cell malignancies on all approved CAR T-cell agents in late January 2024.